The treatment groups showed higher rates of pain-freedom at 2 hours compared to placebo, with the highest response rate observed in the acetaminophen group (31.3%). Low-dose naltrexone alone also demonstrated a 17.3% higher response rate than placebo for headache pain-freedom.
Significant improvement in VAS scores and RNAc-HFO levels after stimulation in the identified target area (LdACC), indicating effective pain modulation.
The study found that gepants produced a statistically significant drug effect on pain freedom and reduction of bothersome symptoms in women, with an average treatment effect of 9.5% for pain freedom and 10.2% for bothersome symptoms. In contrast, the effects in men were negligible, indicating a preferential efficacy in women.
Patients treated with naltrexone/acetaminophen experienced a significant reduction in monthly migraine days, with 66.7% achieving a 75% reduction during the double-blind phase and 100% achieving at least a 50% reduction during the open-label phase.
Acupuncture significantly reduces migraine intensity, frequency of attacks, and number of migraine days by improving energy metabolism.
The primary outcome is a reduction in migraine frequency and intensity after 12 weeks of treatment. Secondary outcomes include improvements in photosensitivity, retinal vessel changes, and blood biomarker concentrations related to vascular tone.
The systematic review aims to provide evidence on the effectiveness of music therapy in reducing the intensity and frequency of migraine attacks, potentially leading to improved patient outcomes and quality of life.
Propranolol significantly reduced stroke risk in female migraine patients, particularly those with migraines without aura, showing a lower hazard ratio for stroke at 1, 2, 5, and 10 years compared to non-users.
The study aims to establish the safety and tolerability of CBD-enriched CHE, with secondary objectives including assessing changes in headache frequency, pain intensity, sleep, mood, function, and quality of life.
The proposed sequence of treatments is expected to minimize headache days by efficiently identifying effective medications through a structured trial process.
The machine prescription policy resulted in a 35% reduction in time-to-response (3.750 months) compared to expert guidelines, with no significant increase in treatment costs per patient, indicating improved treatment efficiency.
Potential positive outcomes include reduced headache frequency and severity, improved quality of life for women suffering from hormonal-related headaches, and evidence-based recommendations for clinicians.
49.1% of patients reported that IN ketamine was 'very effective' for their headaches, and 35.5% noted a significant improvement in their quality of life (QOL).
The study found that mind-body therapy altered the relationship between evoked pain and migraine symptoms, particularly improving disability and pain severity.
Verapamil was found to be effective in preventing hemiplegic migraine episodes, with an odds ratio of 2.68, indicating a significant reduction in the frequency of events compared to other treatments.
Significant reduction in headache frequency and related disability was observed 6 and 12 months after the therapy program, with median headache days decreasing from 30 at baseline to 13 at 12 months, and PedMidas scores improving from 30 to 7.
Overall, depression scores decreased significantly during treatment, indicating a positive response to rTMS. However, the rate of improvement varied based on the presence of headache/migraine, which showed greater initial improvement but a faster slowing in the rate of decrease over time.
Patients reported a mean improvement of 72% in headaches on the treated side. Significant reductions in headache days (from 18.3 to 11.1 days/month), severity (from 7.8 to 5.4), and need for emergency care (from 3.6 to 0.71 visits/year) were observed after treatment of TOS.